ST Germain D J Co. Inc. Has $10.39 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• ST Germain D J Co. Inc. increased its stake in Zimmer Biomet Holdings, Inc. by 11.6% to $10.39 million in the second quarter, owning approximately 0.06% of the company.
• Zimmer Biomet's stock is currently valued at $96.94, with a market capitalization of $19.20 billion, and analysts have set an average price target of $113.16.
• The company declared a quarterly dividend of $0.24 per share, representing an annualized yield of 1.0%, to be paid on October 31st.

ST Germain D J Co. Inc. raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11.6% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 113,873 shares of the medical equipment provider's stock after acquiring an additional 11,801 shares during the period. ST Germain D J Co. Inc. owned about 0.06% of Zimmer Biomet worth $10,386,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the business. Garde Capital Inc. bought a new stake in shares of Zimmer Biomet in the first quarter worth $29,000. Washington Trust Advisors Inc. acquired a new stake in Zimmer Biomet in the 1st quarter valued at $30,000. Columbia River Financial Group LLC bought a new stake in Zimmer Biomet during the 1st quarter worth about $30,000. Accent Capital Management LLC acquired a new position in shares of Zimmer Biomet during the 1st quarter worth about $35,000. Finally, Cullen Frost Bankers Inc. grew its holdings in shares of Zimmer Biomet by 1,452.4% in the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 305 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Rothschild & Co Redburn initiated coverage on Zimmer Biomet in a report on Thursday, September 18th. They set a "buy" rating and a $130.00 target price on the stock. Evercore ISI cut their price objective on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. UBS Group upped their price target on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research report on Friday, August 8th. Finally, Stifel Nicolaus lifted their price objective on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a "buy" rating in a research report on Friday, September 19th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Zimmer Biomet has an average rating of "Moderate Buy" and a consensus target price of $113.16.

Zimmer Biomet Stock Down 2.1%

ZBH opened at $96.94 on Friday. The stock has a fifty day moving average of $100.48 and a 200-day moving average of $99.23. The company has a market capitalization of $19.20 billion, a P/E ratio of 23.59, a P/E/G ratio of 2.28 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the prior year, the company posted $2.01 earnings per share. Zimmer Biomet's revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet's payout ratio is presently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.39% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.